Announcements Trials
Browse Landscape

Status

Completed 13Active not recruiting 7Recruiting 3Withdrawn 1No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

nilotinib 4dabrafenib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3Nivolumab 3tazemetostat 2talimogene laherparepvec 2ceritinib 2TIC10 compound 2Suspensions 2Prednisone 2Powders 2Panobinostat 2Melphalan 2Lenalidomide 2Ipilimumab 2Everolimus 2Dexamethasone 2Crizotinib 2Bortezomib 2Bevacizumab 2Axitinib 2zanubrutinib 1zanidatamab 1venetoclax 1veliparib 1tucatinib 1talquetamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × INDUSTRY × Androgen Antagonists × Clear all
NCT03523338 2025-12-10

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

Aragon Pharmaceuticals, Inc.

No longer available
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡